Table 1.

Elagolix‐Induced Reduction and Recovery in BMD Estimated by the Longitudinal Mixed Effects Model

	Estimate	SE	P value
Treatment duration (year)	−0.0051	0.0024	0.035
Treatment duration (year) × recovery duration (year)	−0.0003	0.0039	0.940
Treatment duration (year) × 200 mg BID (versus 150 mg QD)	−0.0188	0.0036	< 0.001
Treatment duration (year) × recovery duration (year) × 200 mg BID (versus 150 mg QD)	0.0086	0.0052	0.098

The model was adjusted for age, weight, race (white versus non‐white), use of genitourinary system medication and sex hormones as medication, anemia (versus no blood diseases), other blood diseases (versus no blood diseases), and ovary lesion.

BID = Twice daily; QD = once daily.